Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Zoetis: Pets and Profits


In terms of revenue, Zoetis is the world leader in its specific market.

Zoetis (NYSE:ZTS) is the only publicly-traded pure-play in the animal health and vaccines market. This is a global growth business, making it an attractive long-term investment.

In terms of revenue, the company is the world leader in this market, and until this year, it was a wholly-owned division of Pfizer (NYSE:PFE).

In January, Pfizer sold 20% of Zoetis to the public through an IPO. In June, Pfizer offered the remaining 80% to Pfizer shareholders through an exchange offer. The offer was substantially oversubscribed. Zoetis is now a fully independent company.

Zoetis offers animal health products for livestock and domestic pets. Sales of livestock-related products have grown at an 18.5% rate over the last three years. Pet-related products have grown at a 12.5% rate.

Zoetis is financially strong, with $468 million in cash and cash equivalents, and average net profit margins of 10%.

The debt/capital ratio is currently on the high side at 83% because Zoetis raised $3.65 billion through a bond issue just before the IPO.

Full-year earnings per share are expected to range from $1.36 to $1.42 on revenues of $4.425 billion to $4.525 billion. The current consensus among analysts is for full-year earnings of $1.40 on revenues of $5.522 billion.

Major research groups, including Argus, see Zoetis' earnings per share growing at an 11% compound rate over the next five years. Both Argus and Deutsche Bank research have a 12-month target price of $38 for Zoetis. They also agree on a 2014 earnings per share estimate of $1.62. There is a dividend of $0.26 per share per year for a current yield of less than 1%.

Following the conclusion of the Pfizer exchange offer, the stock dipped to a low of $28.97. My rating is to buy Zoetis below $30.

Editor's Note: This article was written by John Dessauer of John Dessauer's Outlook for MoneyShow.

Below, find some more great investing and trading content from MoneyShow:

Nutrisystem: Diet Dollars

Bristol-Myers: Blockbuster Pipeline?

Four Healthy Plays From the Chartist

Twitter: @TopProsTopPicks
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos